Biocatalytic transamination process

US10407702B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10407702-B2
Application numberUS-201715665572-A
CountryUS
Kind codeB2
Filing dateAug 1, 2017
Priority dateDec 7, 2012
Publication dateSep 10, 2019
Grant dateSep 10, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.

First claim

Opening claim text (preview).

What is claimed is: 1. A process for preparing an asymmetric compound of Formula I: wherein: R 1 is a leaving group, a protected amino group, NO 2 , or OH or its protected form; R 2 is hydrogen; R 3 is (C═O)OR 5 , CH 2 R 6 , or a protected aldehyde; or, R 2 and R 3 are combined to form a nitrogen containing heterocyclyl selected from R 4 is hydrogen or an amino protecting group; R 5 is C 1-6 alkyl, C 3-10 cycloalkyl, C 4-10 heterocyclyl, aryl, or heteroaryl; and, R 6 is a leaving group or OH or its protected form; comprising a biocatalytic transamination of a compound of Formula II: wherein: R 1 is as defined above; R 2′ is an aldehyde or an aldehyde equivalent; and, R 3′ is R 3 ; or R 2′ and R 3′ are combined to form in the presence of a transaminase polypeptide, a coenzyme, and an amino donor; wherein the transaminase polypeptide is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NO: 172, 174, 176, 178, 180, 182, 184, 186, 188, and 190. 2. The process of claim 1 , wherein the biocatalytic transamination provides a compound of Formula I having an enantiomeric excess of at least 95%. 3. The process of claim 1 , wherein the transaminase polypeptide is SEQ ID NO: 180. 4. The process of claim 1 , wherein the coenzyme is pyridoxal-phosphate (PLP). 5. The process of claim 1 , wherein the amino donor is isopropylamine. 6. The process of claim 1 , wherein the transaminase polypeptide is SEQ ID NO: 180, the coenzyme is PLP, and the amino donor is isopropylamine. 7. The process of claim 1 , wherein R 1 is Br. 8. The process of claim 1 , wherein R 2 and R 3 are combined to form a nitrogen containing heterocyclyl selected from and R 4 is hydrogen. 9. The process of claim 8 , wherein R 2 and R 3 are combined to form and R 4 is hydrogen. 10. The process of claim 1 , wherein R 1 is Br, R 2 and R 3 are combined to form and R 4 is hydrogen. 11. The process of claim 8 , wherein R 2 is hydrogen, R 3 is CH 2 R 5 , R 4 is hydrogen, and R 5 is OH.

Assignees

Inventors

Classifications

  • C12P17/12Primary

    containing a six-membered hetero ring · CPC title

  • transferring nitrogenous groups (2.6) · CPC title

  • Transaminases (2.6.1) · CPC title

  • C07D211/02Primary

    Preparation by ring-closure or hydrogenation · CPC title

  • Amines; Imines · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10407702B2 cover?
A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) …
Who is the assignee on this patent?
Merck Sharp & Dohme
What technology area does this patent fall under?
Primary CPC classification C12P17/12. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).